The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View…

Overview of attention for article published in Lung Cancer: Targets and Therapy, June 2023

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 9,879 followers.

RT @oncoOuLungCA: The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FD… http…

RT @oncoOuLungCA: The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FD… http…

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FD… https://t.co/dlo8KAwLRw

RT @oncoOuLungCA: Additional exclusions of ROS1 fusions | LCTT @DovePress https://t.co/XsbDHoRkiS. A food for thought editorial on harmoniz…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.